Trials / Active Not Recruiting
Active Not RecruitingNCT05824468
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
A Phase II Trial of Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors in Patients With Advanced Cervical Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Although immune checkpoint inhibitors (ICIs) provide a durable response in multiple tumor types, relapse occurs in most patients with solid tumor. However, the benefits of retreatment with ICIs remains controversial. In some studies, retreatment with ICIs has exhibited encouraging efficacy in patients with solid tumors, particularly in melanoma, and non-small cell lung cancer (NSCLC). In this single arm phase 2 trial, we aimed to evaluate the efficacy and safety of the combination of anti-PD1 antibody (zimberelimab) and lenvatinib in patients with advanced cervical cancer who progressed on or after prior ICIs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zimberelimab | Injectable solution |
| DRUG | Lenvatinib | Capsule |
Timeline
- Start date
- 2023-05-10
- Primary completion
- 2024-07-20
- Completion
- 2026-06-30
- First posted
- 2023-04-21
- Last updated
- 2026-03-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05824468. Inclusion in this directory is not an endorsement.